Prima shareholders endorse Immutep buy November 14, 2014 - 4:56PM Shareholders in cancer treatment developer Prima Biomed have approved the company's acquisition of French biopharmaceutical firm Immutep SA. Prima Biomed shareholders gave their consent for the acquisition at the company's annual general meeting in Sydney on Friday. The acquisition, which will cost Prima up to $30 million in cash, shares and warrants, will enable it to significantly expand its drug development portfolio. When Prima announced the proposed acquisition in October, Prima BioMed chair Lucy Turnbull described it as the most significant announcement in its history. Immunotherapy is a process whereby a disease such as cancer is treated by either activating or suppressing components of the immune system to generate a response. Prima shares were steady at 3.9 cents at 1605 AEDT on Friday.